Welcome to our dedicated page for Eliem Therapeutics SEC filings (Ticker: ELYM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings associated with Eliem Therapeutics, Inc. (historically trading under the symbol ELYM) provide a regulatory record of the company’s transition from a neuronal excitability-focused biotechnology business to a clinical-stage developer of therapeutics for immune-mediated and autoimmune-driven inflammatory diseases. These documents include current reports on material events, financial updates and, in later periods, references to the company’s new corporate name, Climb Bio, Inc.
Through its filings, the company reports on transactions such as the acquisition of Tenet Medicines, Inc., the related private placement of common stock and the resulting capital position intended to support the clinical development of its anti-CD19 monoclonal antibody program, budoprutug (also referred to as TNT119). Filings also reference the company’s strategic shift away from its earlier Kv7.2/3 and neuronal excitability programs and its focus on autoimmune-driven inflammatory diseases.
On Stock Titan’s filings page, users can access Eliem’s historical SEC submissions, including current reports that discuss results of operations and financial condition, strategic transactions and corporate changes such as the reported rebranding to Climb Bio, Inc. AI-powered summaries help explain the key points of lengthy filings, highlight material developments and clarify how specific disclosures relate to the company’s evolving business focus and lead therapeutic assets.
Investors researching ELYM can use these filings to trace the company’s regulatory history, understand the context behind major corporate decisions and follow how its identity and pipeline have been described in official documents over time.
Climb Bio, Inc. reported a net loss of $8.7 million for Q2 2025 and $29.4 million for the six months ended June 30, 2025. The company held $22.7 million in cash and $164.0 million in marketable securities (short- and long-term combined), giving available cash, cash equivalents and marketable securities of approximately $187.4 million as of June 30, 2025. Climb Bio had 67.8 million shares outstanding.
The period reflected increased research and development spending related to budoprutug and the CLYM116 license, including a $9.0 million upfront payment under the Mabworks agreement and higher clinical start-up and manufacturing costs for budoprutug after the Tenet acquisition. The company recorded prior acquired IPR&D expense of $51.7 million tied to the June 2024 Tenet acquisition. Management states current resources are expected to fund operations through 2027.
Climb Bio, Inc. announced it furnished a press release reporting its financial results for the quarter ended June 30, 2025. The press release is attached as Exhibit 99.1 and the company states the information is being furnished and not filed for purposes of Section 18 of the Exchange Act, meaning it is provided to investors but not incorporated into other filings by reference.
The company’s common stock trades on The Nasdaq Stock Market under the ticker CLYM. The report is signed on behalf of the registrant by Aoife Brennan, M.B., Ch.B., President and Chief Executive Officer. Financial details themselves are contained in the attached press release.
Thomas Stephen Basil, a director of Climb Bio, Inc. (CLYM), had restricted stock units granted on June 27, 2024 vest after performance milestones were deemed achieved on 08/07/2025, resulting in the acquisition of 100,375 shares of common stock. The award was settled at a $0 per-share price as reported.
Following the vesting event, Mr. Basil's direct beneficial ownership increased to 304,657 shares. The Form 4 discloses that the RSUs were subject to performance-based milestones and continuous service and that the milestones were deemed achieved, causing full vesting of the award.
FAQ
What is the current stock price of Eliem Therapeutics (ELYM)?
What is the market cap of Eliem Therapeutics (ELYM)?
